THE TRANSDERMAL USE OF CYANOBACTERIAL ALGAE, AND/OR EXTRACTS THEREOF, VIA LOW OR HIGH INTENSITY TRANSPORATION DEVICES FOR BEAUTY AND HEALTH ENHANCING PURPOSES
20200222475 ยท 2020-07-16
Inventors
Cpc classification
A61K47/06
HUMAN NECESSITIES
A61K35/748
HUMAN NECESSITIES
A61K8/99
HUMAN NECESSITIES
A61K9/06
HUMAN NECESSITIES
A61K2800/81
HUMAN NECESSITIES
A61K2800/82
HUMAN NECESSITIES
A61K41/0047
HUMAN NECESSITIES
A61K9/14
HUMAN NECESSITIES
A61K9/0014
HUMAN NECESSITIES
A61K2800/83
HUMAN NECESSITIES
International classification
A61K35/748
HUMAN NECESSITIES
A61K41/00
HUMAN NECESSITIES
A61K47/06
HUMAN NECESSITIES
A61K9/00
HUMAN NECESSITIES
A61K9/06
HUMAN NECESSITIES
Abstract
The present invention refers to the transporation, or force-transdermal vehiculation, of cyanobacterial algae or extracts thereof, through electroporation, sonoporation (sound), photoporation (light), radioporation (radio frequency), and through any other transporation tool for enhancing the transdermal penetration of cyanobacterial molecules via the transmission of some force, be it electric, or generated by sound, light and/or radio frequencies. The invention cover the use of whole cyanobacterial algae or extracts thereof, with different levels of transdermal penetration, be it the low intensity transporation, which can be used for deep aesthetic and skin regenerating purposes, as well as dermatological problems; or the high intensity transporation, able to penetrate deep though the dermis, and beyond the hypodermis into organs and tissues, and that can be uses for muscular, osteo-articular and metabolic problems. Following an exhaustive explanation of the invention, we present very significant results in different beauty and health areas.
Claims
1. The transdermal vehiculation of cyanobacterial algae, and/or extracts thereof, via electroporation, sonoporation, radio frequency, photoporation, or any other system using some type of force to allow for the opening of the water and ionic channels of the skin, for beauty and health enhancing purposes.
2. The use, according to claim 1, of specific devices, including without being limited to, electrical currents or impulses, such as ionophoresis, iontophoresis, electrical muscle stimulation, and all forms of electroporation; vibratory currents, such as cavitation, ultrasound and all forms of sonoporation; laser, LED light and all forms of phototherapy; all forms of radio frequencies; thermal devices using heat; any other device capable of opening the skin's pores to allow for the penetration, at different levels of depth, of the large molecules.
3. A preparation, according to claim 1, which contains the whole Klamath AFA algae and/or extracts thereof, and/or whole Spirulina or Spirulina's extracts, and/or any other cyanobacterial algae and/or cyanobacterial extracts, combined with any other substances.
4. A preparation according to claim 2, whereby the other substances include, without being limited to, purified phycocyanins, purified phenylethylamine, proteolytic and lipolytic enzymes, hyaluronic acid, glycosaminoglycans, chlorophyll, carotenes, xantophylls (astaxantin, canthaxanthin, zeaxantin, lutein, licopene), polyphenols, polysaccharides, caffeine, vitamins, minerals and herbs.
5. A preparation, according to claim 1, which is formulated in pharmaceutically acceptable vehicles and excipients, wherein all components of the preparation are suitable for administration by transporation methods.
6. The use of a preparation, according to claim 1, applied transdermally via transporation to a subject for preventing, controlling, mitigating or treating aesthetic problems, such as wrinkles, cellulite, stretch marks, age spots, skin and muscle tone, breast tone and volume.
7. The use of a preparation according to claim 1, applied transdermally via transporation to a subject for preventing, controlling or treating dermatological diseases, including, without being limited to, acne, eczemas, keloids, psoriasis, pimples, scars, wounds.
8. The use of a preparation according to claim 1, applied transdermally via transporation to a subject for preventing, controlling, mitigating or treating muscle and osteo-articular diseases such as arthritis, joint inflammation, joint calcification, tendon inflammation and calcification, cartilage degenerations such as meniscus, osteoporosis.
9. The use according to claim 8, whereby the preparation used for joint and tendons calcification also comprises specific calcium dissolving minerals, including, without being limited to, acetic acid, citric acid, EDTA (ethylenediaminetetracetic acid), sodium bicarbonate and sodium hydroxide.
10. The use of a preparation according to claim 1, applied transdermally via transporation to a subject for preventing, controlling, mitigating or treating metabolic diseases such as lymphatic (diabetes, ageing) and circulatory problems (varicose veins, heavy legs, etc.), obesity, fat accumulation and metabolism.
11. The use of a preparation according to claim 1, applied transdermally via transporation to a subject for preventing, controlling, mitigating or treating organ-centered degenerations, including, without being limited to, hepatitis, gallbladder and kidney stones, intestinal and respiratory problems.
12. The use of a preparation according to claim 1, wherein the quantity of preparation applied transdermally is comprised from 0.1 to 500 gr and preferably of approximately 1 to 10 grs., according to the size of the area to be treated.
13. The use of a preparation according to claim 1, wherein the composition is in the form of a powder to be dissolved in distilled water, or in the form of a creme, gel or liquid suitable for administration by transporation methods.
14. The use according to claim 1, wherein the subject is an animal or human subject.
Description
THE INVENTION
[0005] The invention refers to specific ways to transdermally vehiculate cyanobacterial algae or extracts thereof, such as through electroporation, sonoporation (sound), photoporation (light), radioporation (radio frequency) cavitation, and any other transporation tool which can enhance the transdermal penetration of cyanobacterial molecules. Transporation is achieved via the transmission of some force, be it electric, or generated by sound, light and radio frequencies. These systems, which differ from generic transdermal patches, which are based simply in prolonged contact, use some type of force, be it electrical or other, to promote deeper skin penetration by opening the water and ionic channels within and outside the skin's cells. Such systems can also modulate, via the intensity of the force and the time of the application, the depth of the penetration, achieving a partial penetration of the substance vehiculated down to the dermis, to affect for instance elastin and collagen fibers when using low level transporation intensity or shorter times; while reaching down trough the dermis and into the hypodermis, to affect organs and tissues, via higher intensity and longer time transporation. In this way, these transporation devices allow for the penetration of high molecular weight cyanobacterial molecules such as phycocyanins or large cyanobacterial carotenoids, in order to alleviate and possibly resolve both superficial, epidermis-related beauty and dermatological problems, and deep-rooted skin problems, as well as muscular and bone affections, and possibly even metabolic and organ pathologies.
[0006] If we consider for instance phycocyanins, the typical cyanobacterial molecules that have known antioxidant (Bath V. B. et al. 2000; Benedetti S. et al. 2004; 2010), anti-inflammatory (Hsiao G et al., 2005; Romay C. et al, 1998) and anti-proliferative (Scoglio S. et al, 2016) properties, when applied cosmetically, or even applied through transdermal patches, they can only operate superficially. What makes transporation different from mere cosmetics cremes is that it allows for the penetration of the epidermis down to the dermis, to affect for instance elastin and collagen fibers, and even through the dermis and into the hypodermis with enough concentration as to effectively affect muscles, bones or organs. Our previous patent (PCT/EP 2007 005623/published as WO2008/000431) also covered the cosmetic use of AFA-phycocyanins (the name we use for the specific phycocyanins of Klamath microalgae). However, through cosmetic cremes or transdermal means such as transdermal patches, phycocyanins could not go very deep through the skin, and could have mere cosmetic effects; while with transporation, at low intensity levels they can reach the dermis, affecting elastin, collagen and the connective tissue supporting the skin; while with high intensity transporation devices they can reach through the dermis and, via the hypodermis, the underlying organs and tissues, such as muscle, bones, and the bloodstream.
[0007] The fundamental problem solved by such transdermal means it's bypassing the resistance of the stratum corneum of the our skin: the phospholipidic intercellular belayer of the skin is naturally hydrophobic; and only the long standing research that led to the discoveries by MacKinnon and Agre (Nobel prize in Chemistry in 1993
[0008] As the process consists in the temporary stimulation of an existing physiological structure and function, the process itself is absolutely physiological, and thus generally safe. However, it is a form of artificial modification of the state of the epidermic cells's water and ionic channels, and this is what distinguishes transporation methods, in its different forms (electro, sono, photo, RF, thermal), from mere transdermal cosmetic means, such as transdermal patches, which do not modify the status of water and ionic channels of the skin's cells, and are thus limited to the transdermal vehiculation of only small molecules, characterized by a molecule size and weight small enough so that the skin does not constitute a barrier for them. So, for instance, molecules such as phycocyanins, which are quite large, or even whole cyanobacterial algae, are too big to penetrate into and through the dermis by themselves.
[0009] Once applied through trans-poration methods, phycocyanins, as well as large anti-oxidant and anti-inflammatory molecules contained in the microalgae, such as the AFA-phytochrome described in the above mentioned patent (WO2008/000431) with a molecular weight of approximately 400 kD, can directly and positively affect deep aesthetic and dermatological, as well as muscular, osteo-articular, circulatory and even metabolic diseases, thus bypassing the issue of metabolization through the digestive tract, and throughout the circulatory torrent, which indeed significantly reduces the ability of large, high molecular weight, molecules to arrive to the local, peripheral site where they are needed.
[0010] The invention, thus, does not refer to any specific technology or machinery, but to the fact that any result obtainable with the different transporation devices available, is radically enhanced, both in terms of efficacy, speed and cost, by using as the main substance to be vehiculated cyanobacterial algae, such as Klamath algae (Aphanizomenon flos aquae) and/or Spirulina, and/or any of the cyanobacterial antioxidant and anti-inflammatory molecules concentrated in any cyanobacterial extracts.
[0011] Other substances can be added to the whole cyanobacteria and/or cyanobacterial extracts, such as phenyethylamine, hyaluronic acid, herbs, specific minerals, enzymes, and so on, but always using the whole cyanobacterial microalgae and extracts as the main component of the products.
[0012] The invention consists thus in the transdermal use of a powder, solution, gel or liquid, composed of the whole cyanobacterial algae, be it Klamath AFA, Spirulina or any other, by itself or together with any cyanobacterial extracts concentrating the antioxidant and inflammatory substances such as phycocyanins, phenylethylamine (PEA), MAAs, polyphenols, carotenoids, chlorophyll (Kamat J P et al, 2000; Hartigg U. 1998), etc., to be used trans-topically via different transdermal and trans-poration systems, for health and beauty purposes, through devices that are able to open up the water and ionic channels of the skin. Some of these molecules, such as MAAs and PEA, are quite small, but being embedded in the whole cyanobacterial matrix, they follow the destiny of the larger molecules contained in the matrix.
[0013] The preparation can be constituted also by a mix of different cyanobacteria or cyanobacterial extracts, and can be put into bottles, sachets, or any other containers.
[0014] Even though the invention implies the possibility of using each cyanobacterial algae and each cyanobacterial extract by itself, the preferred preparation is indeed a mix of both the whole cyanobacterial algae and the cyanobacterial extract, such as the one described in the patent WO2008/000431. This is because, while the cyanobacterial extract concentrates some of the most powerful antioxidant and anti-inflammatory substances contained in the microalgae, the whole microalga itself contains further components, such as vitamins, minerals and other nutraceutical molecules, that can add a significant further action to the vehiculated preparation.
[0015] For instance, cyanobacterial algae contain some trace minerals that may not be very effective when ingesting the algae orally, given their dispersion through the overall body metabolism, and the possibility that they may not be able to cross the intestinal membrane; but that, when vehiculated transdermally, they may actually reach the site that needs to be helped and healed much more directly. A relevant example is that of boron, a trace mineral that can be very helpful for the fixation of calcium in the bone, and thus for osteoporosis, and that is present in Klamath algae at a concentration of about 11 mcg./gr., a low quantity in terms of recommended daily intake, and that with the algae taken orally would be relatively ineffective, when we consider that the few micrograms present would be dispersed throughout the body at the level of naonograms, if not picograms. However, even just 11 micrograms, when administered via transporation onto the area affected, can be very relevant and effective.
[0016] This is even more true, when we consider that Klamath algae contains about 15 milligrams/gr. of calcium, a dosage that taken orally represent only a small fraction of the daily requirement, but if injected directly into the area covering the affected bone, can actually be very helpful to all osteo-articular and bone problems.
[0017] The same can be said of : a) essential fatty acids, such as Omega 3 or Omega 6, present in all cyanobacterial algae, but at a level that, when considered in relation to the oral dose, is still relatively low, whereas it become very effective when applied locally through a transdermal device; b) antioxidant vitamins such as the vitamins C, E and some vitamins B, that can be present in small quantity not very effective hen taken orally, but very useful when injected transdermally; c) many trace minerals present in the algae (AFA algae contains more than 70 minerals and trace minerals), which when taken orally may have a too low concentration to be effective, but when injected transdermally directly in the treated area, they actually can be very effective; d) cyanobacterial algae are also rich in carotenoids, chlorophyll, polysaccharides and polyphenols; but given the low oral dosage (3-5 grams), again their concentration is relatively low (except for a few nutrients), but again it becomes very effective when applied locally, thus without systemic dispersion, via transdermal devices.; e) AFA-algae is also rich in phenylethylamine, a molecule endowed with specific neurological, immunological (Babusyte et al. 2014) and analgesic (Mosnaim A D et al., 2014) properties.
[0018] Given the nutritional and nutraceutical richness of cyanobacterial algae, such as Klamath algae or Spirulina, they can generate an optimum synergy with any other phytotherapic and nutraceutical substances. In fact, any single molecule is usually in need of some other molecule playing a supporting role, and in this respect cyanobacterial algae cam provide the best synergy possible. This is why, for each different area of intervention, the cyanobacterial algae, constituting the essential base, can be combined with other substances, each one relevant for the specific area of intervention.
[0019] Therefore, the invention also covers not only the transporation vehiculation of cyanobacterial algae and of their antioxidant and anti-inflammatory extracts, but also the synergic use of cyanobacteria with any other substance able to intervene favorable on the specific area to be treated. Such use of the whole cyanobacterial algae and/or their extracts in association with other synergistic ingredients, can be applied to the following areas: [0020] A) Aesthetic, including problems such as wrinkles, cellulite, stretch marks, age spots, muscle and skin tone, breast volume, etc. [0021] B) Dermatological, including eczema, psoriasis, wounds, scars, etc: [0022] C) Osteo-articular, including arthritis, inflammation of the joint, joint calcifications, inflammation and/or calcifications of the tendons, degeneration of cartilage such as meniscus, osteoporosis, and so on; [0023] D) Muscular, such as muscle lesions, traumas, inflammation and muscle degeneration; [0024] D) Metabolic, such as lymphatic (diabetes, aging) and circulatory problems (varicose veins, heavy legs, etc), obesity, fat metabolism, and so on;
[0025] We shall see how the application of products based on Klamath algae and Spirulina as the preferred cyanobacterial algae can have very effective results when associated with specific ingredients in each specific area of application.
Areas of Application in Detail
[0026] AESTHETICSIn this area we tested the transdermal use, with low voltage electroporation, as well as low frequency sonoporation and RF, and low intensity light, of a product composed of the whole Klamath algae, of Klamath algae's and Spirulina's phycocyanins extracts, combined with different other substances for each specific purposes. The main conditions tested are the most difficult to treat in the field, namely wrinkles, cellulite, stretch marks, tone of skin, tone and volume of breast, scars and keloids, wounds and so on; all conditions that do not require any penetration through the skin and into organs and tissues.
[0027] While for tonification and filling purposes, as wrinkles, stretch marks and wounds we only added, to the main cyanobacterial base, high molecular weight hyaluronic acid; for breakdown purposes, in conditions such as cellulite and keloids, we also added some herbal extracts as well as proteolytic and lipolytic enzymes. [0028] WrinklesWrinkles are mostly the result of aging, and are due to the breakdown of collagen emerging with age, and more specifically with the increase in oxidative and inflammatory processes, of malnutrition that does not provide the body with enough antioxidants and protective nutrition (vitamins, minerals, EFA), and a lowering of the body's ability to regenerate. To respond to this aging phenomenon, different strategies have been used: providing antioxidant and anti-inflammatory molecules to the skin; supplying the skin with missing nutrients; stimulate the skin's ability to regenerate. Cyanobacterial algae allow all these strategies to be used at one time: they contain a wide range of bioavailable nutrients, have a broad spectrum of antioxidant molecules; their phycocyanins have a high anti-inflammatory power (5); finally, recent studies have shown that phycocyanins potentially stimulates the activity of fibroblasts, endogenous molecules that act as collagen and connective tissue precursors, and so are essential for skin and dermis to regenerate (9). Thanks to all these properties, we found that the transdermal application, via low voltage electroporation of a product containing cyanobacterial algae, the whole Klamath algae, Klamath and Spirulina extracts, plus high molecular weight hyaluronic acid, produces profound and rapid results. Here we report a single case example where, in order to verify more specifically the ability to work on wrinkles, we decided to use a high-definition camera to photograph a single very obvious wrinkle before and after treatment in a woman. [
[0031] We have tested some cases to see if the transdermal vehiculation of a product comprised of the whole AFA plus AFA-phycocyanins and Spirulina's phycocyanins extracts, plus some high molecular weight hyaluronic acid, can improve skin tone in humans, and the results have bee astounding, as shown in the following cases:
[0032] a) The case of a 35-year-old woman whose buttocks showed a tendency towards decreasing dermal tone, which was completely re-established after only 3 treatments (
[0033] b) the case of a 47-year-old man with sagging skin in his arms, whose tone was completely re-established after only three treatments (
[0036] The product we used in this case, while having at its core still cyanobacterial algae (AFA, Spirulina) and relative extracts, added as complementary ingredients proteolytic and lipolytic enzymes and herbs. The basis for the efficacy of this product is once again based on the antioxidant and anti-inflammatory activity of the active molecules present in cyanobacterial algae. In particular, phycocyanins have been shown to be active also as anti-platelet aggregation factors, and platelet aggregation plays a role in both venous and lymphatic stagnation (8). Also, phycocyanins have shown to have a significant fibrinolytic activity, which is essentially to break down the fibrin that holds up the the cellulite debris together (9). Finally, both proteolytic and lipolytic enzymes are also fibrinolytic, and thus again capable of dissolving the fibrin that holds cellulite tissue together. We have regularly tested the resolution of cellulite cases with the transdermal application of a cyanobacterial based product. Here we present the case of 54-year-old woman with a type 3 cellulite, who received a significant improvement after only three treatments during the same week (
[0060] At this point, however, we decided to develop a more specific formula for such a painful and widespread problem, that has currently no satisfactory solution, adding to the product described above a mixture of specific minerals, endowed with the ability to generate the lysis and dissolution of calcium deposits. The list of the minerals added to the cyanobacterial formula includes, without being exhaustive, acetic acid, citric acid, EDTA (ethylenediaminetetracetic acid), sodium bicarbonate and sodium hydroxide.
[0061] This formula has been tested, the main ingredient still being the cyanobacterial algae and extracts, plus enzymes plus the above mentioned minerals. We have tested it in over 50 cases of more or less advanced calcification of the joints. Each of the participants in the study was asked to perform an ultrasound scan before the treatment, to evaluate the position and size of the calcification. Each participant with a proven calcification was then treated with the transporation of the above mentioned formula, and the result was verified through a further post-treatment ultrasound scan. In all 50 cases, on average after only four sessions and sometimes after 6 sessions, calcifications were completely dissolved, and the patients completely recovered the mobility of the joint. We believe that the transporation of the above-described formula can be an effective therapeutic solution of a previously unresolved problem that afflicts an ever-growing segment of the population. Here we report only two of the 50 cases that were recorded: [0062] a) a 38-year-old man with a 15 mm (1.5 cm) long shoulder calcification, that was completely removed after four sessions of the trans-poration of the same formula, with the patient recovering the full arm and shoulder functionality (
[0066] As a first proof of this hypothesis/possibility, we treated a child with cystic fibrosis, who had already improved his condition through a nutritional supplement program with Klamath algae and different types of fungal enzymes. The parents agreed to submit the child to a series of sessions where the cyanobacterial product (Klamath algae, AFA-phycocyanincs extract, Spirulina's phycocyanins extract), enhanced by proteolytic and lipolytic enzymes, was applied via electroporation to the chest and the back of the child, to see if this could have an effect on the excessive lung congestion affecting the young cystic fibrosis patient. During each of the three sessions, the child expelled a large amount of lung catarrh, interpreted as a positive sign by both physicians and parents. This case preliminarily proves that the transporation of the above described product is able to penetrate so deep as to penetrate the organs, in the specific case the lungs and bronchial tubes.
REFERENCES
[0067] Babusyte A. et al. 2013. Biogenic amines activate blood leukocytes via trace amine-associated receptors TAAR1 and TAAR2, Journal of Leukocyte Biology, 93: 387-394. [0068] Benedetti S., Scoglio S. et al., 2004. Antioxydant properties of a novel phycocyanin extract from the blue-green alga Aphanizomenon Flos Aquae, in Life Sciences, 75:2353-2362. [0069] Benedetti S., Scoglio S. et al., 2010. Oxygen radical absorbance capacity of phycocyanin and phycocyanobilin from the food supplement Aphanizomenon flos-aquae, in J Med Food. February; 13(1):223-7. [0070] Bhat V. B., et al., 2000. C-phycocyanin: a potent peroxyl radical scavenger in vivo and in vitro, in Biochem Biophys Res Commun. 275(1):20-25; [0071] Cavalchini A., Scoglio S., 2009. Complementary treatment of psoriasis with an AFA-phycocyanins product: a preliminary 10-cases study, International Medical Journal, 16 (3), September, pp. 221-224. [0072] Harttig U., 1998. Chemoprotection by natural chlorophylls in vivo: inhibition of dibenzo[a,l]pyrene-DNA adducts in rainbow trout liver, Carcinogenesis, July; 19(7): 1323-6. [0073] Hsiao G. et al, 2005. C-Phycocyanin, a Very Potent and Novel Platelet Aggregation Inhibitor from Spirulina platensis, J Agric Food Chem. October 5; 53(20): 7734-40. [0074] Kamat J P, et al., 2000. Chlorophyllin as an effective antioxidant against membrane damage in vitro and ex vivo, in Biochim Biophys Acta, September 27; 1487(2-3):113-27. [0075] Kunte M., Desai K., 2017. The Inhibitory Effect of C-phycocyanin Containing Protein Extract (C-PC Extract) on Human Matrix Metalloproteinases (MMP-2 and MMP-9) in Hepatocellular Cancer Cell Line (HepG2).Protein J. June; 36(3):186-195:768. [0076] Kushak, R. I. et al., 2000. Favorable Effects of Blue Green Algae Aphanizomenon Flos Aquae on Rat Plasma Lipid, in Journal of the American Nutraceutical Association, Vol. 2, n3, January, pp. 59-65. [0077] Kushak R. I., et al, 2001. The Effect of Blue-Green Algae Aphanizomenon Flos Aquae on Nutrient Assimilation in Rats, JANA, Vol. 3, no. 4, Winter, pp. 35-39. [0078] Madhyastha H K. et al. 2008. uPA dependent and independent mechanisms of wound healing by C-phycocyanin, in J Cell Mol Med. December; 12(6B):2691-703. [0079] Madhyastha, H. K. et al. 2006. C-phycocyanin transcriptionally regulates uPA mRNA through cAMP mediated PKA pathway in human fibroblast WI-38 cells, in Biochim Biophys Acta. November; 1760(11):1624-30. [0080] Mitragotri S. 2000. Synergistic effect of enhancers for transdermal drug delivery, in Pharm Res. November; 17(11):1354-9. [0081] Mosnaim A D et al. 2014. Analgesic effects of p-phenylethylamine and various methylated derivatives in mice, Neurochem Res. September; 39(9):1675-80. [0082] Nicoli S. et al. 2009. In vitro transscleral iontophoresis of high molecular weight neutral compounds, in Eur J Pharm Sci. March 2; 36(4-5):486-92. [0083] Rafail I. Kushak, et al. 2000. Favorable Effects of Blue Green Algae Aphanizomenon Flos Aquae on Rat Plasma Lipid, Journal of the American Nutraceutical Association, Vol. 2, n3, January pp. 59-65. [0084] Ravi M. et al. 2015. Molecular mechanism of anti-cancer activity of phycocyanin in triple-negative breast cancer cells, BMC Cancer. October 23; 15. [0085] Romay, C. et al. 1998. Antioxidant and antinflammatory properties of C-phycocyanin from blue-green algae, in Inflamm Res, January; 47(1): 36-41. [0086] Scoglio S. et al, 2016. Inhibitory effects of Aphanizomenon flos-aquae constituents on human UDP-glucose dehydrogenase activity, J Enzyme Inhib Med Chem. December; 31(6): 1492-7.